Optimal designs in stability studies

Journal of Biopharmaceutical Statistics

Volumn 16, Issue 1, 2006, Pages 35-59

  Hedayat, A S ^a   Yan, Xu ^b   Lin, Lawrence ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Bracketing Design; Drug development; Fractional factorial; Information matrix; Matrix design; Optimality criterion; Power; Shelf life; Stability studies

Indexed keywords

ARTICLE; MATHEMATICAL ANALYSIS; POPULATION MODEL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

DRUG INDUSTRY; DRUG STABILITY; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 30344464677     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400500406512     Document Type: Article

References (14)

1. Chow, S. C., Liu, J. P. (1995). Statistical Design and Analysis in Pharmaceutical Science: Validation, Process Controls, and Stability. New York: Marcel Dekker.
2. Dewoody, K., Raghavarao, D. (1997). Some optimal matrix designs in stability studies. J. Biopharm. Stat. 7(2):205-213.
3. Dewoody, K., Raghavarao, D. (1999). Use of matrix designs in stability studies: A simulation study. Drug Inform. J. 33:859-868.
4. Food and Drug Administration, Center for Drugs and Biologies, Office of Drug Research and Review. (1987). Guideline for Submitting Documentation for the Stability of Human Drugs and Biologies. Washington, DC: FDA.
5. Food and Drug Administration, Center for drug Evaluation and Research and Center for Biologies Evaluation and Research. (2003a). Guidance for Industry: ICH Q1A(R2) Stability Testing of New Drug Substances and Products. Washington, DC: FDA.
6. Food and Drug Administration, Center for drug Evaluation and Research and Center for Biologies Evaluation and Research. (2003b). Guidance for Industry: ICH Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. Washington, DC: FDA.
7. Food and Drug Administration, Center for drug Evaluation and Research and Center for Biologies Evaluation and Research. (2003c). Draft ICH Consensus Guideline Q1E Stability Data Evaluation. Washington, DC: FDA.
8. Hedayat, S. (2001). Optimal Designs. Lecture notes, University of Illinois at Chicago.
9. Ju, H. L., Chow, S. C. (1995). On stability designs in drug shelf life estimation. J. Biopharm. Stat. 5(2):201-214.
10. Lin, T. Y. D., Chen, W. C. (2003). Overview of stability study designs. J. Biopharm. Stat. 13(3):337-354.
11. Murphy, J. (1996). Uniform matrix stability study designs. J. Biopharm. Stat. 6(4):477-494.
12. Natarajan, J., Altan, S., Raghavarao, D. (1997). Expiration dating of pharmaceutical compounds in relation to analytical variation, degradation rate and matrix designs. Drug Inform. J. 31(2):589-595.
13. Nordbrock, E. (1992). Statistical comparison of stability drug designs. J. Biopharm. Stat. 2(1):91-113.
14. Pong, A., Raghavarao, D. (2000). Comparison of bracketing and matrixing designs for a two-year stability study. J. Biopharm. Stat. 10(2):217-228.